Compare NSSC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NSSC | EVO |
|---|---|---|
| Founded | 1969 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 994.5M |
| IPO Year | 1994 | N/A |
| Metric | NSSC | EVO |
|---|---|---|
| Price | $37.04 | $2.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $48.17 | $7.00 |
| AVG Volume (30 Days) | ★ 373.0K | 28.6K |
| Earning Date | 05-04-2026 | 04-08-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $181,621,000.00 | N/A |
| Revenue This Year | $13.63 | $1.37 |
| Revenue Next Year | $10.05 | $10.05 |
| P/E Ratio | $53.81 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.27 | $2.31 |
| 52 Week High | $47.61 | $4.42 |
| Indicator | NSSC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 37.20 |
| Support Level | $34.77 | $2.32 |
| Resistance Level | $38.07 | $3.82 |
| Average True Range (ATR) | 1.26 | 0.07 |
| MACD | 0.40 | -0.03 |
| Stochastic Oscillator | 74.77 | 0.00 |
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.